Efficacy and tolerability of AP 5346 in patients with recurrent, platinum-resistant ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2010
At a glance
- Drugs AP 5346 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 07 Jan 2010 Status changed from recruiting to completed, as reported in an Access Pharmaceuticals media release.
- 05 Mar 2009 Results reported in a Access Pharmaceuticals media release.
- 21 Oct 2008 Results presented at the Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) symposium.